UBS Group’s Evoke Pharma EVOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,258
| Closed | -$5.56K | – | 10349 |
|
|
2024
Q4 | $5.56K | Buy |
1,258
+1,168
| +1,298% | +$5.82K | ﹤0.01% | 8639 |
|
|
2024
Q3 | $428 | Sell |
90
-2
| -2% | -$11 | ﹤0.01% | 8945 |
|
|
2024
Q2 | $586 | Hold |
92
| – | – | ﹤0.01% | 8853 |
|
|
2024
Q1 | $675 | Sell |
92
-151
| -62% | -$1.28K | ﹤0.01% | 8418 |
|
|
2023
Q4 | $3.06K | Buy |
243
+17
| +8% | +$253 | ﹤0.01% | 8012 |
|
|
2023
Q3 | $3.74K | Buy |
226
+134
| +146% | +$2.19K | ﹤0.01% | 7520 |
|
|
2023
Q2 | $1.83K | Hold |
92
| – | – | ﹤0.01% | 7849 |
|
|
2023
Q1 | $2.1K | Hold |
92
| – | – | ﹤0.01% | 8580 |
|
|
2022
Q4 | $2.97K | Hold |
92
| – | – | ﹤0.01% | 9594 |
|
|
2022
Q3 | $2K | Sell |
92
-385
| -81% | -$12.7K | ﹤0.01% | 9717 |
|
|
2022
Q2 | $19K | Buy |
477
+305
| +177% | +$14.5K | ﹤0.01% | 6937 |
|
|
2022
Q1 | $12K | Buy |
172
+147
| +588% | +$11.7K | ﹤0.01% | 8170 |
|
|
2021
Q4 | $2K | Buy |
25
+9
| +56% | +$1.26K | ﹤0.01% | 9791 |
|
|
2021
Q3 | $3K | Sell |
16
-104
| -87% | -$17.5K | ﹤0.01% | 8804 |
|
|
2021
Q2 | $24K | Sell |
120
-101
| -46% | -$21.6K | ﹤0.01% | 7136 |
|
|
2021
Q1 | $58K | Buy |
221
+209
| +1,742% | +$83.6K | ﹤0.01% | 6394 |
|
|
2020
Q4 | $5K | Sell |
12
-58
| -83% | -$29.9K | ﹤0.01% | 7826 |
|
|
2020
Q3 | $47K | Buy |
70
+66
| +1,650% | +$42.1K | ﹤0.01% | 5695 |
|
|
2020
Q2 | $2K | Buy |
4
+2
| +100% | +$556 | ﹤0.01% | 7625 |
|
|
2020
Q1 | $0 | Sell |
2
-20
| -91% | -$3.84K | ﹤0.01% | 8070 |
|
|
2019
Q4 | $5K | Buy |
+22
| New | +$3.77K | ﹤0.01% | 7572 |
|
|
2019
Q2 | – | Sell |
-14
| Closed | -$3K | – | 7940 |
|
|
2019
Q1 | $3K | Sell |
14
-8
| -36% | -$2.73K | ﹤0.01% | 7333 |
|
|
2018
Q4 | $8K | Sell |
22
-26
| -54% | -$9.62K | ﹤0.01% | 7340 |
|
|
2018
Q3 | $21K | Buy |
48
+45
| +1,500% | +$18K | ﹤0.01% | 6768 |
|
|
2018
Q2 | $1K | Sell |
3
-17
| -85% | -$6.37K | ﹤0.01% | 7820 |
|
|
2018
Q1 | $6K | Sell |
20
-3
| -13% | -$987 | ﹤0.01% | 7139 |
|
|
2017
Q4 | $7K | Buy |
23
+7
| +44% | +$2.9K | ﹤0.01% | 7222 |
|
|
2017
Q3 | $7K | Hold |
16
| – | – | ﹤0.01% | 7062 |
|
|
2017
Q2 | $6K | Hold |
16
| – | – | ﹤0.01% | 7044 |
|
|
2017
Q1 | $7K | Buy |
+16
| New | +$6.55K | ﹤0.01% | 6811 |
|
|
2016
Q4 | – | Sell |
-2
| Closed | -$1K | – | 7829 |
|
|
2016
Q3 | $1K | Sell |
2
-15
| -88% | -$6.87K | ﹤0.01% | 7513 |
|
|
2016
Q2 | $16K | Buy |
+17
| New | +$13.3K | ﹤0.01% | 6458 |
|
|
2016
Q1 | – | Sell |
-9
| Closed | -$4K | – | 7778 |
|
|
2015
Q4 | $4K | Buy |
+9
| New | +$4.58K | ﹤0.01% | 7770 |
|
|
2015
Q1 | – | Sell |
-3
| Closed | -$2K | – | 8959 |
|
|
2014
Q4 | $2K | Buy |
+3
| New | +$2.48K | ﹤0.01% | 9391 |
|
Other funds holding EVOK
NCM
BL
BRF
TRCT
SS
NA
UBS Group's EVOK Position: Q1 2025 in Review
UBS Group sold out of Evoke Pharma (EVOK) in Q1 2025, closing a stake of 1,258 shares — an estimated $5.56K sold.
UBS Group first reported a position in EVOK in Q4 2014 and held it in 34 quarters. The position peaked at $58K in Q1 2021. 10 funds tracked by Wall St. Rank hold EVOK as of Q1 2025.
- UBS Group reported no remaining Evoke Pharma position as of Q1 2025 after selling out during the quarter.
- UBS Group sold 1,258 Evoke Pharma shares in Q1 2025, an estimated $5.56K.
- UBS Group first reported a position in Evoke Pharma in Q4 2014 and held it in 34 quarters.
- UBS Group's Evoke Pharma position peaked at $58K in Q1 2021.
- 10 funds tracked by Wall St. Rank held Evoke Pharma as of Q1 2025.
Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.